{"id":"fg-m108","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1256141","moleculeType":"Small molecule","molecularWeight":"225.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details for FG-M108 are limited in public literature, the drug is being developed by FutureGen Biopharmaceutical as an immunotherapy candidate. Based on the company's pipeline focus, it likely modulates immune checkpoint signaling to reinvigorate T-cell mediated anti-tumor responses, though the precise molecular target requires confirmation from clinical trial data.","oneSentence":"FG-M108 is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:12:31.210Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (indication under clinical investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT07383922","phase":"PHASE3","title":"A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","startDate":"2026-02-28","conditions":"Pancreatic Cancer","enrollment":524}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["M108"],"phase":"phase_3","status":"active","brandName":"FG-M108","genericName":"FG-M108","companyName":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","companyId":"futuregen-biopharmaceutical-beijing-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FG-M108 is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity. Used for Solid tumors (indication under clinical investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}